Oncotarget

Case Reports:

This article has an addendum. Addendum in: Oncotarget. 2023; 14:438-438.

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report

Mayank Rao, Meenakshi Bhattacharjee, Scott Shepard and Sigmund Hsu

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:6038-6042. https://doi.org/10.18632/oncotarget.27203

Metrics: PDF 1245 views  |   Full Text 1797 views  |   ?  


Abstract

Mayank Rao1, Meenakshi Bhattacharjee2, Scott Shepard3 and Sigmund Hsu1

1 The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA

2 Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA

3 Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA 19140, USA

Correspondence to:

Sigmund Hsu,email: [email protected]

Keywords: papillary; craniopharyngioma; BRAF V600E; dabrafenib; neuro-oncology

Received: May 20, 2019     Accepted: August 12, 2019     Published: October 15, 2019

ABSTRACT

We report a case of a patient with newly diagnosed, locally extensive and cystic, suprasellar papillary craniopharyngioma successfully treated with single-agent Dabrafenib. The patient was symptomatic with gait imbalance with falls, lethargic episodes, fatigue and incontinence. Diagnostic imaging demonstrated a cystic suprasellar tumor extending into the third ventricle causing obstructive hydrocephalus. The tumor was partially debulked, and bilateral shunts were placed. NGS sequencing demonstrated BRAF V600E mutation, and the patient was prescribed dual agent Dabrafenib and Trametinib. However, due to insurance denial for Trametinib, he only received single-agent Dabrafenib (150mg BID). The treatment resulted in a major response (over two years), including reduction of the tumor cyst, and improvement of the clinical symptoms. No adverse events have been reported. The patient continues on Dabrafenib (150 mg BID) with a steady reduction in tumor size, and improvement in cognitive function leading to independent living.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27203